BioSpace News Archive

Drug Development

FDA Grants Merck’s Keytruda Priority Review for Cervical Cancer

The FDA accepted Merck & Co.’s supplemental Biologics License Application and granted Priority Review for Keytruda in advanced cervical cancer.

March 13, 2018
·
3 min read
·
Mark Terry
Drug Development

Proteostasis Therapeutics Snags Breakthrough Designation

The U.S. Food and Drug Administration granted Proteostasis Therapeutics’ investigational cystic fibrosis add-on therapy the Breakthrough Therapy Designation.

March 13, 2018
·
2 min read
·
Alex Keown
Drug Development

AbbVie’s Elagolix Dazzles in Phase III Trial

AbbVie and Neurocrine Biosciences announced that its Phase III ELARIS UF-II trial of elagolix for uterine fibroids met its primary endpoint.

March 13, 2018
·
2 min read
·
Mark Terry
What’s wrong with being busy? How to work less and accomplish more

What’s wrong with being busy? According to career experts, psychologists and other healthcare providers, and industry leaders, a whole a lot.

March 13, 2018
·
7 min read
Drug Development

Aeglea BioTherapeutics Updates Phase I/II Trial Data

Aeglea BioTherapeutics announced new repeat dose data from its Phase I/II trial of AEB1102 (pegzilarginase) in patients with Arginase 1 Deficiency.

March 13, 2018
·
3 min read
·
Mark Terry
Drug Development

Protalix BioTherapeutics Treatment for Ulcerative Colitis Shows Positive Data

Protalix BioTherapeutics believes it’s on the right track in developing an oral medicine for ulcerative colitis that could potentially replace current TNF-inhibitor therapies that are administered via injection or infusion.

March 13, 2018
·
2 min read
·
Alex Keown
Drug Development

FDA Halts Advaxis Study Following Patient Death

The FDA placed a hold on Advaxis’ Phase I/II trial following the death of a patient.

March 13, 2018
·
2 min read
·
Alex Keown
Biotech Bay

Are Life Science Companies Falling Behind Tech Companies?

Tech companies have been making significant forays into the life sciences and a new report suggests that life science companies are in danger of falling behind their tech brethren..

March 13, 2018
·
2 min read
·
Mark Terry
Life sciences companies at risk of falling behind technology competitors in race to address evolving consumer demands

Life sciences companies are at risk of being marginalized by technology companies and new entrants, warns the new EY report Progressions 2018 Life Sciences 4.0: Securing value through data-driven platforms.

March 13, 2018
·
4 min read
Drug Development

Poxel Announces Initiation of TIMES 2 and TIMES 3 Trials for the Phase 3 Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan

Poxel SA announced the initiation of the TIMES 2 and TIMES 3 trials for the Phase 3 program for Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan.

March 13, 2018
·
3 min read